Cargando…

A pilot study investigating circulating trimethylamine N‐oxide and its precursors in dogs with degenerative mitral valve disease with or without congestive heart failure

BACKGROUND: Pathophysiologic mechanisms for the development and progression of degenerative mitral valve disease (DMVD) remain elusive. Increased concentrations of circulating trimethylamine N‐oxide (TMAO) and its precursors choline and l‐carnitine are associated with the presence and severity of he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karlin, Emily T., Rush, John E., Freeman, Lisa M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	SMALL ANIMAL
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335534/ https://www.ncbi.nlm.nih.gov/pubmed/30511765 http://dx.doi.org/10.1111/jvim.15347

Ejemplares similares

Pulmonary Vein‐to‐Pulmonary Artery Ratio is an Echocardiographic Index of Congestive Heart Failure in Dogs with Degenerative Mitral Valve Disease
por: Merveille, A.‐C., et al.
Publicado: (2015)

Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study
por: Besche, Beatrice, et al.
Publicado: (2020)

Echocardiographic indices and severity of mitral regurgitation in dogs with preclinical degenerative mitral valve disease
por: Larouche‐Lebel, Éva, et al.
Publicado: (2019)

Radiographic lung congestion scores in dogs with acute congestive heart failure caused by myxomatous mitral valve disease
por: Koster, Liza, et al.
Publicado: (2023)

Pathologic Manifestations on Surgical Biopsy and Their Correlation with Clinical Indices in Dogs with Degenerative Mitral Valve Disease
por: Lee, J., et al.
Publicado: (2015)

Short‐Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study
por: Chetboul, V., et al.
Publicado: (2017)

Effect of a specially formulated diet on progression of heart enlargement in dogs with subclinical degenerative mitral valve disease
por: Oyama, Mark A., et al.
Publicado: (2023)

Clinical and laboratory findings and survival time associated with cardiac cachexia in dogs with congestive heart failure
por: Ineson, Deanna L., et al.
Publicado: (2019)

Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary‐care veterinary practices in the United Kingdom
por: Mattin, M. J., et al.
Publicado: (2018)

Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease
por: Yata, Mariko, et al.
Publicado: (2019)

Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease
por: Wilshaw, Jenny, et al.
Publicado: (2021)

Effect of prespecified therapy escalation on plasma NT‐proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease
por: Hezzell, Melanie J., et al.
Publicado: (2018)

Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)
por: Coffman, Melissa, et al.
Publicado: (2021)

Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom
por: Mattin, Madeleine J., et al.
Publicado: (2018)

The classical and alternative circulating renin‐angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease
por: Hammond, Hillary H., et al.
Publicado: (2023)

The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs
por: Vezzosi, Tommaso, et al.
Publicado: (2021)

Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease
por: Kim, H.‐S., et al.
Publicado: (2016)

Retrospective study of dilated cardiomyopathy in dogs
por: Freid, Kimberly J., et al.
Publicado: (2020)

Cardiac cachexia in cats with congestive heart failure: Prevalence and clinical, laboratory, and survival findings
por: Santiago, Sasha L., et al.
Publicado: (2019)

Atrial Fibrillation as a Prognostic Indicator in Medium to Large‐Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure
por: Jung, S.W., et al.
Publicado: (2016)

Preliminary Investigation of Cardiovascular–Renal Disorders in Dogs with Chronic Mitral Valve Disease
por: Martinelli, E., et al.
Publicado: (2016)

Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs
por: Nakamura, K., et al.
Publicado: (2017)

Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral valve disease
por: Guglielmini, Carlo, et al.
Publicado: (2020)

Radiographic quantification of left atrial size in dogs with myxomatous mitral valve disease
por: Lam, Christopher, et al.
Publicado: (2021)

Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
por: McManamey, Anna K., et al.
Publicado: (2023)

Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study
por: Boswood, Adrian, et al.
Publicado: (2020)

Echocardiographic Estimates of Right Ventricular Systolic Function in Dogs with Myxomatous Mitral Valve Disease
por: Chapel, E.H., et al.
Publicado: (2017)

Echocardiographic predictors of first onset of atrial fibrillation in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2020)

Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease
por: Druzhaeva, Natalia, et al.
Publicado: (2021)

Echocardiographic estimation of left ventricular‐arterial coupling in dogs with myxomatous mitral valve disease
por: Osuga, Tatsuyuki, et al.
Publicado: (2021)

Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease
por: Iwasa, Naoki, et al.
Publicado: (2023)

Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial
por: Wess, Gerhard, et al.
Publicado: (2020)

Utility of Tissue Doppler Imaging in the Echocardiographic Evaluation of Left and Right Ventricular Function in Dogs with Myxomatous Mitral Valve Disease with or without Pulmonary Hypertension
por: Baron Toaldo, M., et al.
Publicado: (2016)

Reproducibility of echocardiographic indices of left atrial size in dogs with subclinical myxomatous mitral valve disease
por: Hsue, Weihow, et al.
Publicado: (2020)

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
por: Boswood, A., et al.
Publicado: (2016)

Effect of Body Position, Exercise, and Sedation on Estimation of Pulmonary Artery Pressure in Dogs with Degenerative Atrioventricular Valve Disease
por: Rhinehart, J.D., et al.
Publicado: (2017)

A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease
por: Newhard, Daniel K., et al.
Publicado: (2018)

Correction of serum chloride concentration in dogs with congestive heart failure
por: Adin, Darcy, et al.
Publicado: (2020)

Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease
por: Tidholm, A., et al.
Publicado: (2015)

Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8k5qdd56r9vq1mc9lghrg9rnhl